Phenylbutyrylhydroxamic Acid

Phenylbutyrylhydroxamic Acid

SCHEMBL1350853

O=C(CCCc1ccccc1)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 15/20 1.00
HDAC2 Q92769 11/20 1.00
HDAC8 Q9BY41 9/20 1.00
HDAC6 Q9UBN7 7/20 1.00
HDAC3 O15379 7/20 1.00
HDAC5 Q9UQL6 4/20 1.00
ALOX5 P09917 1/20 0.86
HDAC10 Q969S8 5/20 0.73
HDAC11 Q96DB2 5/20 0.73
HDAC4 P56524 4/20 0.73
HDAC9 Q9UKV0 4/20 0.73
HDAC7 Q8WUI4 3/20 0.73
NCOR2 Q9Y618 3/20 0.72
MAPK1 P28482 1/20 0.64
ADRA1A P35348 1/20 0.64
SLC6A3 Q01959 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylbutyrylhydroxamic Acid SCHEMBL27961036 0.98 HDAC1 (0.96) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL5020669 0.96 HDAC1 (0.93) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL5020670 0.96 HDAC1 (1.00) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL5020559 0.94 HDAC1 (0.96) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL3844327 0.92 HDAC1 (1.00) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL5807174 0.92 HDAC1 (1.00) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL22190384 0.92 HDAC1 (1.00) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL8610138 0.92 HDAC1 (1.00) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL7043051 0.89 HDAC2 (0.90) HDAC1HDAC2HDAC8HDAC6HDAC3
SCHEMBL1980549 0.89 HDAC1 (1.00) HDAC1HDAC2HDAC8HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116554069-A Preparation method and preparation equipment of formate compound 绍兴贝斯美化工股份有限公司 2023-08-08 CN claimed
CN-110015974-A A kind of preparation method of cyclododecanone oxime 万华化学集团股份有限公司 2019-07-16 CN claimed
CN-107488090-A A kind of efficient catalytic asymmetry preparation method of N cyclopropyl nitrone compound 东北师范大学 2017-12-19 CN claimed
CN-106146350-B A kind of new method of synthesizing amino formic acid oxime ester derivative 华南理工大学 2017-10-20 CN claimed
CN-107011201-A Preparation method of amide 南京工业大学 2017-08-04 CN claimed
CN-106146350-A A kind of new method of synthesizing amino methylcarbamoyl oximino ester derivant 华南理工大学 2016-11-23 CN claimed
CN-116554069-A Preparation method and preparation equipment of formate compound 绍兴贝斯美化工股份有限公司 2023-08-08 CN disclosed
US-20220168717-A1 NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME INSTITUTE FOR BASIC SCIENCE (KR) 2022-06-02 US disclosed
US-11344872-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same INSTITUTE FOR BASIC SCIENCE (KR) 2022-05-31 US disclosed
US-20220048988-A1 CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME CHILDREN'S NATIONAL MEDICAL CENTER 2022-02-17 US disclosed
EP-3849607-A1 CELLS COMPRISING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF PREPARING AND USING THE SAME CHILDREN'S NATIONAL MEDICAL CENTER (US) 2021-07-21 EP disclosed
US-20210040184-A1 ANTI-HIV ANTIBODIES ATRECA INC (US) 2021-02-11 US disclosed
US-20210040185-A1 ANTI-HIV ANTIBODIES ATRECA INC (US) 2021-02-11 US disclosed
EP-1107953-A1 HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-06-20 EP disclosed
WO-2000012477-A1 HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-03-09 WO disclosed
CN-1029613-C Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflamatory agents AMERICAN HOME PROD (US) 1995-08-30 CN disclosed
CN-1058771-A Method for making of oxime carbamate and oxime carbonate ester and uses thereof AMERICAN HOME PROD (US) 1992-02-19 CN disclosed
EP-0200377-B1 HYDROXAMATES SQUIBB & SONS INC (US) 1991-10-09 EP disclosed
EP-0200377-A2 Hydroxamates E.R. Squibb & Sons, Inc. (US) 1986-11-05 EP disclosed
US-4604407-A Hydroxamates E. R. SQUIBB & SONS, INC. (US) 1986-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220168717-A1 NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME COASY, NOTUM, MRPL21 HDAC1 1597/4885HDAC2 2165/4885HDAC8 2653/4885
US-11344872-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same COASY, NOTUM, MRPL21 HDAC1 1465/4885HDAC2 1983/4885HDAC8 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.